Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | MicrobiomeTrials← Back to trialsNCT07192432
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-11-18Est. Completion: 2033-09
Enrollment target: 27 participants Locations- Valkyrie Clinical Trials, Los Angeles, California, United States
- SCRI Denver DDU at HealthOne, Denver, Colorado, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Hackensack Medical Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- UT MD Anderson Cancer Center, Houston, Texas, United States
- VCU Massey CTO Phase I Solid Team, Richmond, Virginia, United States
Other microbiome trials you might be interested in
Locally Advanced (Unresectable) or Metastatic Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy …
Hangzhou, ChinaEst. completion Jun 30, 2027
Advanced Solid Tumor
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tum…
Sarasota, United StatesEst. completion May 15, 2030